Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Figure 1

Study enrollment and patient flow. Diagram of the 35 patients screened for eligibility. One patient was ineligible due to Richter’s transformation during screening period. Two patient’s voluntary withdrew consent prior to intervention.